NCT07093762View on ClinicalTrials.gov

Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC

Not yet recruitingOBSERVATIONAL
Enrollment

35

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel

Atezolizumab: 1200 mg IV every 3 weeks; Bevacizumab: 15 mg/kg IV every 3 weeks; Carboplatin: AUC 5 IV every 3 weeks; Paclitaxel: 175 mg/m² IV every 3 weeks. Treatment cycles: After 4-6 cycles, continue Atezolizumab + Bevacizumab as maintenance therapy until disease progression or unacceptable toxicity.

Trial Locations (1)

Unknown

The 900th Hospital of the Joint Logistic Support Force, PLA, Fuzhou, Fujian, China, 350025, Fuzhou

All Listed Sponsors
collaborator

900 Hospital of Joint Logistics Support Force of PLA

OTHER

lead

Fuzhou General Hospital

OTHER